Post by
Noteable on Mar 23, 2024 11:32am
ONCY Corporate Investor Presentation
January 2024 ... Latest Corporate Investor Presentation
https://oncolyticsbiotech.com/wp-content/uploads/2024/01/Oncolytics.Deck_.January.pdf
March 07, 2024 - ONCY Q4 2023 & full year financial results
https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-fourth-quarter-and-full-year-2023-financial-results-and-operational-highlights/
"New translational data in breast and pancreatic cancer reported in the fourth quarter continued to highlight pelareorep’s role in stimulating tumor-directed immune responses and shaping the tumor microenvironment, affirming its immunotherapeutic mechanism of action (MOA).
These [ Bracelet & Goblet] studies also point to the potential use of tumor-infiltrating lymphocytes, or TILs, as a clinical biomarker for future studies and patient care based on a positive association with tumor responses.
We are optimistic about the potential for pelareorep to provide improved outcomes for cancer patients and look forward to updating investors and our key stakeholders on our registrational readiness and progress as the year unfolds,” concluded Dr. Coffey.
** Comments on Phase 3 Breast Cancer Registrational Study
“Positive 2023 data further de-risked pelareorep and re-defined Oncolytics as a late-stage cancer company. Data from the randomized BRACELET-1 breast cancer trial in HR+/HER2- metastatic patients, reported in June using a March 3, 2023 cut-off date, nearly tripled response rates in the test arm compared to the control arm. Additionally, median progression-free survival was 50% higher in the test arm, and the hazard ratio was 0.29. In the coming months, we expect to report overall survival results from the BRACELET-1 study and define a registrational path that will focus on patients with metastatic HR+/HER2- disease and utilize a pelareorep/paclitaxel combination. Productive, ongoing discussions with our clinical collaborators and potential strategic partners have sharpened and enriched our thinking on the design of this study,” said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics.
** Results of Goblet 1/2 Trial in first line pancreatic cohort presented at ESMO 2023:
https://oncolyticsbiotech.com/wp-content/uploads/2023/10/ESMO_2023_PDAC_poster-FINAL1a.pdf
With these results in hand, we have expanded enrollment in the anal cancer cohort, and, in pancreatic cancer, we intend to initiate an adaptive trial in first-line patients this year. This registration-enabled study will be a landmark achievement for Oncolytics and evaluate the GOBLET pancreatic cohort treatment regimen that was granted Fast Track designation by the FDA.
** Third-line metastatic colorectal cancer patients receiving pelareorep, atezolizumab, and trifluridine/tipiracil (Cohort 3) recorded a 40% disease control rate and met the pre-specified success criteria according to the Simon two-stage methodology.
These findings are encouraging given that exhaustion of tumor-infiltrating lymphocytes, resulting from late stage of disease and extensive prior chemotherapy, may have limited their ability to expand in response to treatment. Notably, this is the second GOBLET study cohort in a row that has met its success criteria, further supporting pelareorep’s ability to synergize with atezolizumab. These data also support pelareorep’s immunologic mechanism of action and will inform our plans for further development.”
https://oncolyticsbiotech.com/press_releases/oncolytics-achieves-success-criteria-for-efficacy-in-the-third-line-colorectal-cancer-cohort-of-the-goblet-study/
https://oncolyticsbiotech.com/wp-content/uploads/2023/10/ESMO_2023_CRC-FINAL.pdf
Comment by
Noteable on Mar 23, 2024 7:44pm
February 2024 - Immunotherapy for Cancer in India - a complete guide Unlike typical viruses that cause illness, oncolytic viruses target cancerous tissues, offering a promising treatment option. https://www.denvaxindia.com/blog/immunotherapy-for-cancer-in-india-a-complete-guide/
Comment by
ENEMENEMYNEMO on Mar 24, 2024 11:53am
Hey B O T, thanks for the rehashing of all the old news quite useless , algorithm needs tweaking. You got anything new to share??
Comment by
Azzak34 on Mar 24, 2024 12:01pm
Your grammar needs tweaking. There's no hurry to post, just re-read what you've wrote and fix the numerous errors. The extra few seconds are worth it I promise.
Comment by
Noteable on Mar 24, 2024 2:01pm
Well, if I seem to be"reshashing" your wild conspiracy "bot" allegations, then so be it.
Comment by
Peladawn on Mar 24, 2024 2:15pm
This post has been removed in accordance with Community Policy
Comment by
Quentin30 on Mar 27, 2024 2:26pm
NO NO NO... ONCY is NOT yet regsitered, so whenever the BLA is submitted, whatever manufacturing process is in place is the one they will register. You're trying to mislead people here into thinking this is something of significance. ONCY has no news, this was a bg fat nothing burger... just like you.